week 3 semaglutide side effects by Week: Pharmacist's Timeline Semaglutide Side Effects: What to

The glucagon-like peptide-1 receptor agonist (GLP-1 RA) is already approved for use in the treatment of obesity and for weight management

As of early 2026, several potent single, dual, and triple incretin receptor agonists are in Phase 2/3 trials for MASH including : Survodutide : A dual glucagon (GCGR)/GLP-1 receptor agonist that has shown significant MASH resolution in Phase 2 trials

Studies show up to 25-39% of weight lost on GLP-1s can come from lean mass - without intentional resistance training and adequate protein

After surgery, fluid usually serous fluid comprising blood plasma from ruptured blood vessels and inflammatory fluid produced by the injured cells has a tendency to accumulate in the region between the skin and muscle, called the dead space.

The company aims to leverage a "differentiated opportunity" to break into the lucrative sector by inventing a new GIP/GLP which in addition to delivering profound weight loss, could also lower bad cholesterol by 50%-60%